
Treace Medical Concepts, Inc.: updates and filings
Price
$4.42
November 20, 2026Market cap $285M
What Ploutos Investor adds for Treace Medical Concepts
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 6, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 6, 2026Results of operationsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 7, 2026Results of operationsForm8-K
- Jul 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 20, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 8, 2026Shares registered for employeesFormS-8
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 8, 2026Results of operationsForm8-K
- Apr 9, 2026Results of operations, officer or director change, Regulation FD disclosureForm8-K
- Apr 6, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 6, 2026Additional annual meeting materialFormDEFA14A
- Apr 6, 2026Annual meeting proxy statementFormDEF 14A
- Feb 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 27, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 13, 2026Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 6, 2026 | 8-K | Results of operations | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 7, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 20, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 8, 2026 | S-8 | Shares registered for employees | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 8, 2026 | 8-K | Results of operations | Document |
| Apr 9, 2026 | 8-K | Results of operations, officer or director change, Regulation FD disclosure | Document |
| Apr 6, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 6, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 6, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 27, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 13, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 21, 2015.
The full analysis
What do Treace Medical Concepts's filings show?
The filings are where every one of Treace Medical Concepts's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.